secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000899923-24-000065
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics appoints Mark S. Davis to Board, expanding to nine members
--------------------------------------------------------------------------

- Mark S. Davis appointed as Class I Director effective December 10, 2024, expanding Board from eight to nine.
- Davis will serve on Audit and Finance Committee; deemed independent and an audit committee financial expert.
- Received restricted stock unit award of $350,000 vesting one year from grant date.
- Davis spent nearly 40 years at Deloitte & Touche LLP, last as National Managing Partner of Deloitte Private.
- Also serves on boards of Yext, Inc., NYU-Winthrop Hospital, and Adelphi University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000065/0000899923-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000065/mygn-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer